0.60
-0.0017(-0.28%)
Currency In USD
| Previous Close | 0.6 |
| Open | 0.6 |
| Day High | 0.62 |
| Day Low | 0.59 |
| 52-Week High | 4.58 |
| 52-Week Low | 0.59 |
| Volume | 114,505 |
| Average Volume | 5.36M |
| Market Cap | 3.08M |
| PE | -0.13 |
| EPS | -4.51 |
| Moving Average 50 Days | 0.92 |
| Moving Average 200 Days | 1.36 |
| Change | -0 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $5.9 as of December 24, 2025 at a share price of $0.598. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $474.76 as of December 24, 2025 at a share price of $0.598.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment
GlobeNewswire Inc.
Yesterday at 1:45 PM GMT
Access the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced
Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
GlobeNewswire Inc.
Dec 18, 2025 1:30 PM GMT
THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been a
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth
GlobeNewswire Inc.
Nov 26, 2025 1:45 PM GMT
THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner seg